AffaMed and EverInsight merger announced

Home/Pharma News | Posted 13/11/2020 post-comment0 Post your comment

AffaMed Therapeutics announced a merger agreement with EverInsight Therapeutics on 10 October 2020.  

Business Aquisition V13F07

AffaMed is a biopharmaceutical company that has focussed on developing therapeutics for ophthalmologic diseases and neurological and psychiatric disorders. In merging, EverInsight’s candidate drugs for treatment of these conditions will be added to AffaMed’s existing portfolio. Going forward, the merged companies will maintain the name AffaMed Therapeutics and will continue to develop treatment options for these disorders with strengthened global R & D capabilities. AffaMed and EverInsight both emerged from the CBC Group (formerly known as C-Bridge Capital), a China-based healthcare-dedicated investment company.

AffaMed’s existing portfolio includes the rights for biosimilars of ranibizumab (Lucentis®) and aflibercept (Eylea®) in China and Singapore. The company  has partnerships/agreements with other companies such as South Korea’s Samsung Bioepis [1] and Japan’s Kissei Pharmaceutical. The latter hopes to yield the commercialization of an agent for Parkinson’s disease (KDT-3594).

It was also announced that Dr Dayao Zhao has been appointed as CEO of the combined company. In their statement, the merging companies showcased the experience of Dr Zhao who has previously served as CEO of EverInsight, and of Eucure Pharmaceuticals. He has also held senior leadership positions at Pfizer, the Development China organization, Johnson and Johnson’s pharmaceutical division, and Genzyme; and holds a PhD from Harvard Medical School and an MD degree from Peking University Medical School. Dr Zhao reiterated that, in the merger, EverInsight will bring a strong portfolio in ophthalmologic, neurological and psychiatric disorders. This includes a neurosteroid nasal spray, PH94B, for social anxiety disorder which is moving into phase III development; a product that has licensing rights from VistaGen Therapeutics in Greater China, Korea and Southeast Asia. In addition, he stressed that in China, the new AffaMed will now be well positioned as the partner of choice in ophthalmologic diseases and neurological and psychiatric disorders.

Related articles
Samsung Bioepis and AffaMed to start trastuzumab trial in China

Samsung Bioepis makes deals for copy biologicals in China

1. GaBI Online - Generics and Biosimilars Initiative. Samsung Bioepis and AffaMed to start trastuzumab trial in China []. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Nov 13]. Available from: 

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2020 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
GaBI news digest for 14 October 2022
56 AA011042
Home/Pharma News Posted 14/10/2022
Novartis is set to spin-off Sandoz
Guidance V13F21
Home/Pharma News Posted 16/09/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010